Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

The past week has seen a flurry of activity across various sectors, with several small- and mid-cap stocks delivering notable gains and drawing significant investor attention. From healthcare innovators making strides in cutting-edge treatments to digital asset adopters capitalizing on the growing cryptocurrency trend, and companies executing strategic partnerships and achieving product breakthroughs, these stocks have seized market momentum through a combination of solid fundamentals and strategic moves. This article delves into the key developments propelling these companies forward and what their performance indicates about the broader trends shaping today’s dynamic investment landscape.

---

Also Read: Why This Gold Junior’s Strategic Partnership and Strong Fundamentals Fuel a Major Run?

Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.

---

1. Anbio Biotechnology (NNNN)

Market Cap as of June 25: $3.46 Billion

Anbio Biotechnology (NASDAQ: NNNN) focuses on developing molecular diagnostics and biotech platforms for global health solutions. It has gained attention for its rapid growth in Asia.

GLOBAL EXHIBITION PARTICIPATION: Anbio Biotechnology has participated in three major international exhibitions, EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ACMTT 2025 in Bangkok, where the company showcased its diagnostic innovations.

COMPREHENSIVE DIAGNOSTIC PORTFOLIO: Anbio features a wide range of diagnostic solutions, including:

FLUORESCENCE IMMUNOASSAY (FIA) SYSTEMS: Supports 90 test items, offering rapid and quantitative detection across various clinical areas.

DRY CHEMISTRY ANALYZERS: Compact and user-friendly systems for essential biochemical testing, ideal for decentralized settings.

RAPID TEST KITS: Lateral flow and immunoassay-based kits for on-site diagnostics.

MOLECULAR DIAGNOSTIC SYSTEM: Includes LAMP-based Rapid Mdx System and real-time RT-PCR reagents, enabling faster nucleic acid detection.

VETERINARY DIAGNOSTICS SUITE: Comprehensive solutions for veterinarians, integrating immunoassays, biochemical testing, and molecular diagnostics.

STRATEGIC COMMITMENT TO INNOVATION AND ACCESSIBILITY: Anbio’s participation in these exhibitions reflects its mission to reshape diagnostics through collaboration, innovation, and accessibility. The company aims to connect with partners and professionals who share its vision of smarter, more inclusive healthcare.

GLOBAL EXPANSION AND LOCAL ENGAGEMENT:  Anbio has product registrations in over 100 countries and a growing network of international partners.

STRONG R&D CAPABILITIES: Anbio’s strong R&D capabilities and diverse portfolio position it to meet the growing demand for faster, more accurate, and decentralized testing solutions.

Stock Performance

Anbio’s stock rose 167.26% this week and 210.71% for the month. Year-to-date performance stands at a staggering 317.33%.

---

2. GeneDx Holdings (WGS)

Market Cap as of June 25: $2.59 Billion

GeneDx Holdings (NASDAQ: WGS) provides genomic testing and data-driven diagnostics that help clinicians make personalized medicine decisions. It is extensively expanding its footprint in rare and pediatric diseases.

AAP RECOMMENDATION: The American Academy of Pediatrics (AAP) has updated its guidelines to recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID). This is a significant endorsement that legitimizes the use of advanced genetic testing in pediatric medicine.

MARKET EXPANSION: The updated guidelines open up a large and untapped market for GeneDx. General pediatricians, who are the front line of pediatric care, are now empowered to order these tests directly, bypassing the need to refer patients to geneticists, who often have long waitlists.

COST-EFFECTIVENESS AND BETTER OUTCOMES: Exome and genome testing are now recognized as more cost-effective and clinically beneficial when used earlier in the diagnostic process. This can lead to faster and more accurate diagnoses, reducing the average five-year diagnostic odyssey to a fraction of that time.

INCREASED REIMBURSEMENT: The new guidelines are expected to facilitate broader reimbursement from insurance providers, including major commercial payors and Medicaid programs. This will make genetic testing more accessible and affordable for families.

STRONG MARKET POSITION: GeneDx is a leader in genomic testing, with extensive expertise and a large dataset of over 800,000 exomes and genomes. The company’s standard exome and genome results are available in as little as three weeks, which is a competitive advantage.

Stock Performance

Shares jumped 35.90% over the past week and 35.01% for the month, adding to its impressive 237.92% return over the last year.

---

3. Verve Therapeutics (VERV)

Market Cap as of June 25: $995.73 Million

Verve Therapeutics (NASDAQ: VERV) is a biotechnology company pioneering gene-editing therapies for cardiovascular disease, using base editing technology for permanent genetic fixes.

ELI LILLY’S ACQUISITION OFFER: Eli Lilly and Company has agreed to acquire Verve Therapeutics (NASDAQ: VERV) for up to $1.3 billion. This includes an immediate cash payment of $10.50 per share, totaling approximately $1 billion, plus a contingent value right (CVR) of up to $3.00 per share.

PREMIUM OVER MARKET VALUE: The acquisition offer represents a 113% premium over Verve Therapeutics’ 30-day average share price as of June 16, 2025. This significant premium is a strong indicator of the value Lilly sees in Verve’s technology and pipeline.

PROMISING PIPELINE: Verve Therapeutics is developing single-dose gene-editing therapies for atherosclerotic cardiovascular disease (ASCVD). The flagship program, VERVE-102, targets the PCSK9 gene, which is known to play a crucial role in regulating low-density lipoprotein (LDL) cholesterol, often referred to as “bad” cholesterol.

POSITIVE CLINICAL DATA: Initial results from the Phase 1b trial of VERVE-102 are encouraging. The therapy was well-tolerated, with no treatment-related serious adverse events (SAEs) and no clinically significant laboratory abnormalities observed. Dose dependency was established, with mean reductions in blood LDL-C ranging from 21% to 53% across different dose levels.

FDA FAST TRACK DESIGNATION: VERVE-102 has been granted FDA Fast Track designation, which can accelerate the development and review process. This designation is a clear recognition of the potential of the therapy to address significant unmet medical needs.

Stock Performance

Verve gained 78.15% this week, bringing its YTD return to 98.05% and maintaining strong momentum with a 117.74% gain over the past year.

---

Read Next: This Biotech Stock Just Secured $4.25 Million in Private Placement Deal To Strengthen In Oncology Space.

Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.

4. Cidara Therapeutics (CDTX)

Market Cap as of June 25: $607.51 Million

Cidara Therapeutics (NASDAQ: CDTX) is a biotechnology company developing long-acting antiviral and anti-infective therapeutics, including treatments for influenza and other serious infections.

UPSIZED PUBLIC OFFERING: Cidara Therapeutics announced a public offering of 7.9 million shares of its common stock at $44.00 per share. The gross proceeds are expected to raise $350.0 million. The offering is expected to close on June 26, 2025, subject to customary closing conditions.

PROMISING UNIVERSAL FLU SHOT UPDATE: Cidara Therapeutics presented a promising update for its universal flu shot, CD388, which is a long-acting antiviral drug. A single dose of CD388 provided 58% to 76% protection against symptomatic seasonal influenza for 24 weeks, depending on the dosage, compared to a placebo. These results are numerically better than traditional flu vaccines, which offer 40% to 45% protection against influenza.

ANALYST REACTIONS: 

Needham analyst Joseph Stringer described the results as “significant” and noted that they de-risk Phase 3 development. He models $1.5 billion in non-risk-adjusted peak sales for Cidara Therapeutics’ drug.

RBC Capital Markets analyst Brian Abrahams called the results “impressive,” with every dose clearing his 50% protective effectiveness bar and the highest dose exceeding his best-case view for 65% effectiveness.

Both analysts highlighted the potential for CD388 to target immunocompromised patients and high-risk individuals, estimating a market of 13 million people in the U.S.

MARKET POTENTIAL: The highest dose of CD388 was up to 76% effective, which analysts described as a “home run.” The initial target market for CD388 includes immunocompromised patients and high-risk individuals, but there is potential to expand into broader populations.

RBC Capital Markets’ Brian Abrahams models a $3 billion out-year worldwide sales opportunity for CD388, describing it as a potentially transformative flu prevention alternative.

REGULATORY MILESTONES: CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration in June 2023. Cidara announced the completion of enrollment for its Phase 2b NAVIGATE trial in December 2024. The positive Phase 2 results increase confidence in the potential for pivotal trial development, which could initiate early next year.

Stock Performance

Cidara rose 109.01% this week and 82.26% this month. It’s delivered a massive 300.34% return over the past year.

---

5. Geospace Technologies (GEOS)

Market Cap as of June 25: $215.80 Million

Geospace Technologies (NASDAQ: GEOS) designs and manufactures instruments for seismic data acquisition, primarily serving the oil and gas industry and defense sectors.

MAJOR PETROBRAS CONTRACT: Geospace Technologies was awarded a multi-year contract by Petrobras for a high-value Permanent Reservoir Monitoring (PRM) system. The contract involves the supply and installation of nearly 500 km of Geospace’s proprietary OptoSeis® fiber optic technology in the Mero Fields 3 and 4 offshore Brazil in the Santos Basin.

OPTOSEIS® TECHNOLOGY: The OptoSeis PRM system is designed to continuously monitor deepwater oil reservoirs, enabling Petrobras to maximize resource extraction. OptoSeis technology offers superior data quality with high dynamic range, wide bandwidth, superior fidelity, low crosstalk, and pressure-balanced design, making it an ideal solution for deepwater monitoring.

STRATEGIC DIVERSIFICATION: Geospace Technologies has been diversifying its business segments to reduce dependence on the cyclical energy market. The company’s rebranding to “Solutions for a Smarter Future” and realignment of its business segments highlight its pivot towards modernizing water infrastructure and other high-growth areas.

STRONG FINANCIAL POSITION: Geospace operates with virtually no long-term debt and holds approximately $20 million in cash and short-term investments. The company’s current ratio of 5.59 indicates solid financial health, providing the stability needed to invest in high-growth segments without relying on outside capital.

Stock Performance

GEOS shares increased 144.56% this week and are up 183.67% for the month. Over the year, the stock gained 87.22%.

---

6. Eyenovia (EYEN)

Market Cap as of June 25: $26.00 Million

Eyenovia (NASDAQ: EYEN) is a clinical-stage ophthalmic biopharma company developing microdose therapeutics for eye diseases using its Optejet technology.

$50 MILLION PRIVATE PLACEMENT: Eyenovia announced a $50 million private placement with institutional investors to build a reserve of the HYPE token, part of its new cryptocurrency treasury strategy. This significant capital raise provides the company with the financial resources to pursue its strategic initiatives and enhance its market positioning.

APPOINTMENT OF NEW CIO: Hyunsu Jung was appointed as Chief Investment Officer and Board Member. This move adds expertise and leadership to the company, particularly in the realm of cryptocurrency and investment strategy.

STRATEGIC INTEGRATION OF CRYPTOCURRENCY: Eyenovia is pioneering the integration of cryptocurrency into its treasury by building a reserve of Hyperliquid’s native token, HYPE. The company has acquired approximately 1.04 million HYPE tokens at an average purchase price of about $34.

CONTINUED FOCUS ON CORE BUSINESS: Despite the cryptocurrency initiatives, Eyenovia is focusing on the development of the Gen-2 Optejet User-Filled Device. The company plans to register this device with the FDA by September 2025, which is a crucial step in expanding its product offerings and market presence.

FIRST NASDAQ-LISTED COMPANY TO STOCKPILE HYPE: Eyenovia is the first U.S. publicly listed company to build a strategic treasury of Hyperliquid’s native token, HYPE. This pioneering move could attract attention from both traditional and crypto investors, potentially broadening the company’s investor base.

Stock Performance

The stock surged 203.70% this week and 344.33% over the month, significantly rebounding from a -82.65% one-year decline.

Conclusion

The past week has been a period of notable momentum and transformation for these standout companies. With developments ranging from clinical advancements and regulatory wins to financial restructuring and bold strategic shifts, each has carved a unique path in its respective sector. As markets continue to respond to innovation, investor sentiment, and macroeconomic signals, the progress and decisions of these companies will play a critical role in shaping future industry dynamics and uncovering new growth opportunities.